This inflammation releases mediators, which can destroy collagen and connective tissue, possibly affecting epidermal maturation,' Dermatologist William Kwan said.
Sean Bohen, executive vice-president of global medicines development and chief medical officer at AstraZeneca, said: "This is an important step forward for Tagrisso and a significant opportunity to bring a breakthrough medicine to patients with non-small cell lung cancer in China, where epidermal growth factor receptor mutation rates are some of the highest in the world.
